Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1969 May;48(5):810–822. doi: 10.1172/JCI106039

The role of aminogenic glucagon secretion in blood glucose homeostasis

Roger H Unger 1, Akira Ohneda 1, Eugenio Aguilar-Parada 1, Anna M Eisentraut 1
PMCID: PMC322289  PMID: 5780193

Abstract

Hyperaminoacidemia is a powerful stimulus of pancreatic glucagon secretion. These studies were designed to elucidate the role of aminogenic hyperglucagonemia in glucoregulation. Conscious dogs with previously implanted indwelling venous catheters were employed. The results support the view that a role of glucagon is to limit blood glucose decline during hyperaminoacidemia.

First, a significant negative correlation between the area of glucagon increment during the 1st 20 min of a 10 amino acid infusion and the maximum fall in glucose concentration was observed. Second, when endogenous glucagon secretion was suppressed by means of a continuous glucose infusion, hyperaminoacidemia induced a maximal glucose decline which averaged 35 mg/100 ml, differing significantly from mean maximal fall of 3 mg/100 ml, which normally occurs in the presence of endogenous hyperglucagonemia. Third, when, during hyperglycemic suppression of endogenous glucagon secretion, 50 mμg of exogenous glucagon/min was infused via the mesenteric vein with the amino acids, the fall in glucose was reduced to an average of 5 mg/100 ml. Similarly when pancreozymin, administered during the combined infusion of glucose and amino acids, overcame glucose suppression of endogenous glucagon secretion, plasma glucose did not fall.

Similar results were obtained when aminogenic hyperglucagonemia was prevented by other means. Hyperlipacidemia, induced by infusing a triglyceride emulsion and giving heparin injections, also suppressed aminogenic hyperglucagonemia in two of four experiments; in these two dogs glucose fell 15 and 11 mg/100 ml. In a final group of experiments, the canine pancreas was resected except for the uncinate process, which is virtually devoid of α-cells. In two dogs, in which this procedure resulted in zero portal venous glucagon levels, the administration of amino acids and/or pancreozymin resulted in a glucose decline of 14 and 16 mg/100 ml, despite the reduced β-cell population resulting from the subtotal pancreotectomy.

It thus appears that the secretion of pancreatic glucagon during hyperaminoacidemia in association with insulin secretion, serves to limit the decline of glucose concentration.

Full text

PDF
810

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BENCOSME S. A., LIEPA E. Regional differences of the pancreatic islet. Endocrinology. 1955 Nov;57(5):588–593. doi: 10.1210/endo-57-5-588. [DOI] [PubMed] [Google Scholar]
  2. Best J., Catt K. J., Burger H. G. Non-specificity of arginine infusion as a test for growth-hormone secretion. Lancet. 1968 Jul 20;2(7560):124–126. doi: 10.1016/s0140-6736(68)90416-9. [DOI] [PubMed] [Google Scholar]
  3. Buchanan K. D., Vance J. E., Dinstl K., Williams R. H. Effect of blood glucose on glucagon secretion in anesthetized dogs. Diabetes. 1969 Jan;18(1):11–18. doi: 10.2337/diab.18.1.11. [DOI] [PubMed] [Google Scholar]
  4. Dupre J., Curtis J. D., Unger R. H., Waddell R. W., Beck J. C. Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest. 1969 Apr;48(4):745–757. doi: 10.1172/JCI106032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fajans S. S., Floyd J. C., Jr, Knopf R. F., Conn F. W. Effect of amino acids and proteins on insulin secretion in man. Recent Prog Horm Res. 1967;23:617–662. doi: 10.1016/b978-1-4831-9826-2.50017-9. [DOI] [PubMed] [Google Scholar]
  6. Floyd J. C., Jr, Fajans S. S., Conn J. W., Knopf R. F., Rull J. Insulin secretion in response to protein ingestion. J Clin Invest. 1966 Sep;45(9):1479–1486. doi: 10.1172/JCI105455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. KENNY A. J. Extractable glucagon of the human pancreas. J Clin Endocrinol Metab. 1955 Sep;15(9):1089–1105. doi: 10.1210/jcem-15-9-1089. [DOI] [PubMed] [Google Scholar]
  8. KNOPF R. F., CONN J. W., FAJANS S. S., FLOYD J. C., GUNTSCHE E. M., RULL J. A. PLASMA GROWTH HORMONE RESPONSE TO INTRAVENOUS ADMINISTRATION OF AMINO ACIDS. J Clin Endocrinol Metab. 1965 Aug;25:1140–1144. doi: 10.1210/jcem-25-8-1140. [DOI] [PubMed] [Google Scholar]
  9. LOCHNERJDE V., EISENTRAUT A. M., UNGER R. H. THE EFFECTS OF COCL-2 ON GLUCAGON LEVELS IN PLASMA AND PANCREAS OF THE RAT. Metabolism. 1964 Sep;13:868–874. doi: 10.1016/0026-0495(64)90055-1. [DOI] [PubMed] [Google Scholar]
  10. MOSINGER F. PHOTOMETRIC ADAPTATION OF DOLE'S MICRODETERMINATION OF FREE FATTY ACIDS. J Lipid Res. 1965 Jan;6:157–159. [PubMed] [Google Scholar]
  11. Madison L. L., Seyffert W. A., Jr, Unger R. H., Barker B. Effect on plasma free fatty acids on plasma glucagon and serum insulin concentrations. Metabolism. 1968 Apr;17(4):301–304. doi: 10.1016/0026-0495(68)90097-8. [DOI] [PubMed] [Google Scholar]
  12. Meade R. C., Kneubuhler H. A., Schulte W. J., Barboriak J. J. Stimulation of insulin secretion by pancreozymin. Diabetes. 1967 Mar;16(3):141–144. doi: 10.2337/diab.16.3.141. [DOI] [PubMed] [Google Scholar]
  13. Merimee T. J., Lillicrap D. A., Rabinowitz D. Effect of arginine on serum-levels of human growth-hormone. Lancet. 1965 Oct 2;2(7414):668–670. doi: 10.1016/s0140-6736(65)90399-5. [DOI] [PubMed] [Google Scholar]
  14. Ohneda A., Aguilar-Parada E., Eisentraut A. M., Unger R. H. Control of pancreatic glucagon secretion by glucose. Diabetes. 1969 Jan;18(1):1–10. doi: 10.2337/diab.18.1.1. [DOI] [PubMed] [Google Scholar]
  15. RANDLE P. J., GARLAND P. B., HALES C. N., NEWSHOLME E. A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963 Apr 13;1(7285):785–789. doi: 10.1016/s0140-6736(63)91500-9. [DOI] [PubMed] [Google Scholar]
  16. Rabinowitz D., Merimee T. J., Burgess J. A., Riggs L. Growth hormone and insulin release after arginine: indifference to hyperglycemia and epinephrine. J Clin Endocrinol Metab. 1966 Oct;26(10):1170–1172. doi: 10.1210/jcem-26-10-1170. [DOI] [PubMed] [Google Scholar]
  17. UNGER R. H., EISENTRAUT A. M., McCALL M. S., MADISON L. L. Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. J Clin Invest. 1962 Apr;41:682–689. doi: 10.1172/JCI104525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Unger R. H., Ketterer H., Dupré J., Eisentraut A. M. The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. J Clin Invest. 1967 Apr;46(4):630–645. doi: 10.1172/JCI105565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. WOOL I. G., KRAHL M. E. Incorporation of C14-histidine into protein of isolated diaphragms: interaction of fasting, glucose and insulin. Am J Physiol. 1959 Aug;197:367–369. doi: 10.1152/ajplegacy.1959.197.2.367. [DOI] [PubMed] [Google Scholar]
  20. YALOW R. S., BERSON S. A. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960 Jul;39:1157–1175. doi: 10.1172/JCI104130. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES